Abstract
JE-CV (IMOJEV®, Sanofi Pasteur, France) is a live attenuated virus vaccine constructed by inserting coding sequences of the prM and E structural proteins of the Japanese encephalitis SA14-14-2 virus into the genome of yellow fever 17D virus. Primary immunization with JE-CV requires a single dose of the vaccine. This article reviews clinical trials of JE-CV in children aged up to 6 years conducted in countries across South-East Asia. Strong and persistent antibody responses were observed after single primary and booster doses, with 97% of children seroprotected up to five years after booster vaccination. Models of long-term antibody persistence predict a median duration of protection of approximately 30 years after a booster dose. The safety and reactogenicity profiles of JE-CV primary and booster doses are comparable to other widely used childhood vaccines.
Keywords:
IMOJEV®; Japanese encephalitis; flaviviridae; pediatrics; vaccines.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Antibodies, Viral / blood
-
Asia, Southeastern
-
Child
-
Child, Preschool
-
Clinical Trials as Topic
-
Encephalitis, Japanese / prevention & control*
-
Humans
-
Immunization Schedule
-
Infant
-
Japanese Encephalitis Vaccines / administration & dosage
-
Japanese Encephalitis Vaccines / adverse effects*
-
Japanese Encephalitis Vaccines / immunology*
-
Membrane Glycoproteins / genetics
-
Vaccines, Attenuated / administration & dosage
-
Vaccines, Attenuated / adverse effects
-
Vaccines, Attenuated / immunology
-
Vaccines, Synthetic / administration & dosage
-
Vaccines, Synthetic / adverse effects
-
Vaccines, Synthetic / immunology
-
Viral Envelope Proteins / genetics
-
Yellow Fever Vaccine / genetics
Substances
-
Antibodies, Viral
-
Japanese Encephalitis Vaccines
-
Membrane Glycoproteins
-
Vaccines, Attenuated
-
Vaccines, Synthetic
-
Viral Envelope Proteins
-
Yellow Fever Vaccine
-
glycoprotein E, Japanese encephalitis virus
-
prM protein, Flavivirus